Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus VANTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus VANTIN.
CEFIZOX vs VANTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Cefpodoxime proxetil is a semisynthetic third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
100-200 mg orally twice daily for 10-14 days for community-acquired pneumonia; 100 mg orally twice daily for 5-7 days for acute exacerbations of chronic bronchitis; 100 mg orally twice daily for 10 days for uncomplicated skin and skin structure infections; 100 mg orally twice daily for 3-7 days for uncomplicated urinary tract infections; 200 mg orally twice daily for 10 days for complicated urinary tract infections.
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
The terminal elimination half-life in adults with normal renal function is about 2.2-2.8 hours. In children, it is approximately 1.5-2 hours. Prolonged half-life in renal impairment (up to 9-10 hours in severe impairment) requires dose adjustment.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Approximately 80-90% of cefpodoxime is excreted unchanged in the urine within 24 hours, mainly by glomerular filtration and tubular secretion. A small fraction is eliminated via bile and feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic